Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Catalpol in Diabetes: Pharmacology, PK, and Safety
2026-09-22
The reference review integrates preclinical evidence that Catalpol, also known as Catalpinoside, may improve glucose regulation and protect against diabetic kidney, cardiovascular, nervous-system, and bone complications through multi-pathway control of inflammation, oxidative stress, apoptosis, and metabolism. Its discussion of pharmacokinetics and safety is particularly useful for interpreting animal dosing, blood–brain barrier penetration, oral administration potential, and the limitations that remain before clinical translation.
-
D-Lin-MC3-DMA: From Mechanism to Translation
2026-09-22
D-Lin-MC3-DMA is more than a familiar ionizable lipid: it is a framework for connecting pH-responsive chemistry, RNA payload biology, machine-learning-guided formulation, and translational decision-making. This article examines how to use MC3 rationally across hepatic gene silencing and mRNA delivery while respecting the limits of preclinical evidence.
-
PR-619: A Mechanistic Probe for DUB Biology
2026-09-21
PR-619 is a reversible deubiquitylating enzymes inhibitor for resolving how ubiquitin signaling, proteostasis, autophagy, and cell-state phenotypes interact. This article connects assay design for PR-619 with the progenitor T-cell analysis framework used in a landmark tumor-immunology study.
-
Chaperone-Mediated Autophagy in Muscle Aging
2026-09-21
The reference study identifies chaperone-mediated autophagy (CMA) as an active regulator of skeletal-muscle maintenance rather than a passive response to ageing. Using muscle-specific Lamp2a deficiency, proteomics, calcium assays and aged-mouse rescue experiments, the authors connect declining CMA to SERCA dysfunction, abnormal calcium handling and progressive myopathy.
-
2X Taq PCR Master Mix for C. elegans Studies
2026-09-20
Build faster C. elegans genotyping, cloning, and sequence-verification workflows with a ready-to-use Taq formulation and integrated gel-loading dye. The mix is especially useful for testing pheromone-signaling models because it supports endpoint PCR, direct gel loading, and TA cloning without adding a separate loading-buffer step.
-
Bifidobacterium, FMT, and PET in Chronic HE
2026-09-19
This 2025 European Journal of Neuroscience study compares Bifidobacterium and fecal microbiota transplantation in bile duct ligation rats with chronic hepatic encephalopathy. Its main innovation is the use of regional [18F]PBR146 micro-PET/CT imaging to detect treatment-associated neuroinflammatory differences that were not evident in global brain uptake, behavioral testing, or circulating cytokines.
-
MG-262: Reversible Proteasome Inhibition
2026-09-19
MG-262, also called Z-Leu-Leu-Leu-B(OH)2, is a cell-permeable, reversible inhibitor of proteasome chymotryptic activity. Its controlled use can support proteasome inhibition assay design, apoptosis research, cell cycle arrest studies, and mechanistic analysis of muscle proteostasis.
-
Grazoprevir Hydrate: From Protease Biology to Translation
2026-09-18
A translational framework for using Grazoprevir hydrate and MK-5172 hydrate to connect NS3/4A protease biology, genotype-aware assay design, resistance strategy, pharmacokinetics, and clinically relevant HCV research populations.
-
Bortezomib (PS-341): Proteasome Research Guide
2026-09-17
Bortezomib, also called PS-341, is a reversible 20S proteasome inhibitor used in apoptosis assays, proteostasis studies, and approved cancer treatment. Product-reported benchmarks include 0.1 µM activity in H460 cells and 3.5–5.6 nM activity in canine melanoma cell lines.
-
FGF19–TRIM21–ANXA2 Axis in NPC Angiogenesis
2026-09-17
The reference study identifies an FGF19–TRIM21–ANXA2 regulatory axis that links nasopharyngeal carcinoma progression to tumor angiogenesis. Its combination of clinical profiling, cellular assays, animal models, and ubiquitination analysis supports FGF19 as a candidate biomarker and clarifies how altered protein turnover may enhance the vascular tumor microenvironment.
-
Curcumol, Methionine Metabolism, and HSC Death
2026-09-16
A 2026 study identifies disruption of methionine metabolism as a mechanistic component of curcumol-induced, autophagy-dependent death in hepatic stellate cells. Its partial rescue by S-adenosylmethionine links methyl-donor metabolism to antifibrotic cell-state control while highlighting important limits for translation beyond the LX-2 model.
-
Staurosporine: Kinase Inhibitor Research Guide
2026-09-16
Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor used to interrogate kinase signaling and induce apoptosis in cancer cell lines. Its activity against PKC isoforms, receptor tyrosine kinase autophosphorylation, and VEGF-driven angiogenesis is useful for cancer research, but its breadth limits pathway-specific interpretation.
-
Berberine, Tuft Cells, and Bone Loss
2026-09-15
A 2026 Phytomedicine study identifies a gut–bone mechanism in which berberine increases microbiota-derived butyrate, activates GPR41, and expands intestinal tuft cells during estrogen deficiency. Using ovariectomized rodents, Trpm5-deficient models, organoids, microbiome profiling, and osteoimmune analyses, the work connects barrier repair with restoration of the Th17/Treg balance and reduced bone resorption.
-
DAPI (hydrochloride): DNA-Content Assay Strategy
2026-09-15
DAPI (hydrochloride) is more than a nuclear counterstain: it can anchor a rigorous DNA-content workflow for testing proliferation phenotypes after metabolic perturbation. This guide connects DAPI assay design with mechanistic lessons from GOT1-targeted pancreatic cancer research while clarifying what DNA measurements can—and cannot—prove.
-
FGF4, YY1, and Xist in X-Chromosome Inactivation
2026-09-14
Ma et al. identify FGF4 as an upstream coordinator linking embryonic stem cell differentiation to X-chromosome inactivation through MEK/ERK-dependent YY1 activation and loss of pluripotency-factor repression. The study provides a mechanistic framework for understanding how Xist transcription is initiated, while its mouse ESC model also defines important limits for translation to other cytokine-response systems.